UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 2, 2009
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| | |
| 000-23265 | | 94-3267443 |
| (Commission File Number) | | (IRS Employer ID Number) |
1700 Perimeter Park Drive, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
8018.146-600261 v1
On November 2, 2009, Salix Pharmaceuticals, Ltd. issued a press release announcing that the 60th Annual Meeting of the American Association for the Study of Liver Diseases, being held in Boston, MA, Saturday, October 31 – Tuesday, November 3, 2009, is the venue for two presentations describing the investigation of rifaximin for the maintenance of remission from hepatic encephalopathy. A copy of this press release is attached as Exhibit 99.1.
On November 3, 2009, Salix issued a press release announcing the issuance of a patent by the United States Patent and Trademark Office, entitled “Polymorphic Forms Alpha, Beta, and Gamma of Rifaximin”. A copy of this press release is attached as Exhibit 99.2.
On November 4, 2009, Salix issued a press release announcing that it will present at the 2009 Credit Suisse Healthcare Conference in Phoenix, AZ on Wednesday, November 11 at 3:30 p.m. MT/5:30 p.m. ET. A copy of this press release is attached as Exhibit 99.3.
Also on November 4, 2009, Salix issued a press release announcing that it will host an Analyst Day on Wednesday, November 18, 2009 from 10:00 a.m. to 12:00 noon Eastern Time. A copy of this press release is attached as Exhibit 99.4.
| Item 9.01. | Financial Statements and Exhibits. |
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release dated November 2, 2009. |
| |
| 99.2 | | Press release dated November 3, 2009. |
| |
| 99.3 | | Press release dated November 4, 2009. |
| |
| 99.4 | | Press release dated November 4, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | |
| | | | SALIX PHARMACEUTICALS, LTD. |
| | |
| Date: November 4, 2009 | | | | /S/ ADAM C. DERBYSHIRE |
| | | | Adam C. Derbyshire |
| | | | Executive Vice President and Chief Financial Officer |
